BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 03/14/22

BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for ...

BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference PR Newswire ...

Brainstorm Cell Therapeutics (NASDAQ:BCLI) said the Brazilian Patent Office granted a patent covering a method of manufacturing MSC-NTF cells (NurOwn). The application is titled, "A method of generating cells which secrete Brain Derived Neurotrophic Factor (BDNF), Glial Derived Neurotrop...

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn® PR Newswire NEW YORK , Feb. 15, 2022 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cel...

BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit PR Newswire NEW YORK , Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurod...

Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer&#x...

BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022 PR Newswire NEW YORK , Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces plans for a dosing extension of NurOwn for participants who completed the Expanded Access Protocol (EAP). BCLI shares up 6.2% premarket at $3.95. The FDA recommended that BrainStorm submit an EAP protocol amendment to provide addi...

FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program Three additional doses of NurOwn® will be made available to participants who completed the Expanded Access Protocol FDA approved EAP manufacturing at the Catalent Texas site PR Newswire ...

BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve Pre-specified and post hoc analyses show NurOwn produced clinical benefits in ALS patients with less severe disease Biomarker data show that NurOwn dr...